Tivozanib in Clear-Cell RCC: Adverse Event Management Strategies

EP: 1.Patient Scenario 1: Diagnosis and Risk Stratification of Clear-Cell RCC

EP: 2.Frontline Combination Strategies in Patients With Clear-Cell RCC

EP: 3.Clear-Cell RCC: Impact of Risk Stratification and NCCN Guidelines on 1L Therapy

EP: 4.Multidisciplinary Care and Supplemental Therapy in Clear-Cell RCC

EP: 5.Patient Scenario 2: Second-Line Treatment Options in Clear-Cell RCC

EP: 6.Clear-Cell RCC: Best Practices in Patient Monitoring

EP: 7.TIVO-3: Tivozanib as Third- or Later-Line Therapy in Clear-Cell RCC

Now Viewing

EP: 8.Tivozanib in Clear-Cell RCC: Adverse Event Management Strategies

EP: 9.Tivozanib in Clear-Cell RCC: Dosing Schedule and Adjustments to Therapy

EP: 10.Evolving Treatment Landscape of Clear-Cell Renal Cell Carcinoma

EP: 11.Key Takeaways on the Management of Clear-Cell RCC

EP: 12.Immunotherapy/TKI Combinations Yield Efficacy Benefit in RCC

Summary:

In discussing adverse events associated with tivozanib, one speaker highlights its favorable adverse effect profile, attributing most adverse effects to specific VEGF toxicities rather than off-target effects. Hypertension remains a predominant adverse event, accompanied by manageable occurrences of diarrhea, nausea, fatigue, and mucositis. However, one panelist underscores the potential serious but uncommon toxicities related to VEGF tyrosine kinase inhibitors (TKIs), particularly cardiovascular complications like cardiac failure, ischemic heart disease, thromboembolism, and wound healing issues.

To manage these adverse effects, panelists emphasize the importance of comprehensive patient care. Addressing fatigue involves assessing sleep quality, physical activity, and nutrition. If fatigue persists, a reevaluation of the drug dose and a short treatment break may be considered. Hand-foot syndrome prevention is crucial, involving the prophylactic application of urea-based creams and, if necessary, high-dose topical steroids or treatment breaks.

Multidisciplinary collaboration is crucial in managing adverse effects. One speaker suggests involving nephrology colleagues for proteinuria concerns, dermatology experts for persistent hand-foot syndrome, and cardiology specialists for blood pressure management. Blood pressure monitoring at home, especially for patients with baseline hypertension, allows early intervention with medications like ACE inhibitors or angiotensin receptor blockers. This multidisciplinary approach optimizes adverse effect management, potentially enabling patients to stay on treatment comfortably for extended periods and derive maximal treatment benefits.

Summary is AI-generated and reviewed by Cancer Network editorial staff.